Drug information provided by: Merative, Micromedex®
Ivosidenib is used alone or together with azacitidine to treat newly-diagnosed acute myeloid leukemia (AML) in patients who are 75 years of age or older or who have health problems that prevent the use of certain cancer treatments (chemotherapy). It is also used to treat AML that has come back or has not improved after a previous treatment. Ivosidenib is also used to treat cholangiocarcinoma (bile duct cancer) that has spread or cannot be removed by surgery in patients who have already received a previous treatment. It is used only in patients who have an isocitrate dehydrogenase-1 (IDH1) mutation in their AML or cholangiocarcinoma. Your doctor will test for the presence of this mutation.
This medicine is available only with your doctor's prescription.
This product is available in the following dosage forms:
Portions of this document last updated: May 01, 2023
Copyright: © Merative US L.P. 1973, 2023. All rights reserved. Information is for End User's use only and may not be sold, redistributed or otherwise used for commercial purposes.
Mayo Clinic does not endorse companies or products. Advertising revenue supports our not-for-profit mission.
Check out these best-sellers and special offers on books and newsletters from Mayo Clinic Press.
Make your tax-deductible gift and be a part of the cutting-edge research and care that's changing medicine.